BioCentury
ARTICLE | Clinical News

GI-6207: Phase II started

April 8, 2013 7:00 AM UTC

GlobeImmune began a crossover, U.S. Phase II trial of GI-6207 in 34 patients with metastatic MTC. Patients will receive GI-6207 for 1 year or be observed for 6 months and then treated with GI-6207 for...